Advaxis Inc ADXS:NASDAQ

Last Price$0.34NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change+0.03(10.77%)
Bid (Size)$0.35 (63)
Ask (Size)$0.36 (1)
Day Low / High$0.30 - 0.35
Volume15.4 K
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

Advaxis Inc ( NASDAQ )

Price: $0.34
Change: +0.03 (10.77%)
Volume: 15.4 K
4:00PM ET 12/06/2021
 
 

NanoViricides Inc ( NYSE MKT LLC )

Price: $4.56
Change: +0.10 (2.24%)
Volume: 281.0 K
8:00PM ET 12/06/2021
 
 

OpGen Inc ( NASDAQ )

Price: $1.38
Change: 0.00 (0.00%)
Volume: 456.3 K
4:00PM ET 12/06/2021
 
 

Aravive Inc ( NASDAQ )

Price: $2.60
Change: +0.07 (2.77%)
Volume: 108.3 K
4:00PM ET 12/06/2021
 
 

Calithera Biosciences Inc ( NASDAQ )

Price: $0.73
Change: +0.02 (2.21%)
Volume: 1.2 K
4:00PM ET 12/06/2021
 

Read more news Recent News

Advaxis Says Nasdaq Gives it Extension to Dec. 20 to Complete Biosight Merger, Comply With Listing Requirements
9:52AM ET 11/22/2021 MT Newswires

Advaxis (ADXS) said Monday that it received a letter from Nasdaq's Hearings Panel giving it an extension to Dec. 20 to complete its merger with Biosight...

Advaxis Urges Stockholders to Approve Biosight Merger
9:51AM ET 11/19/2021 MT Newswires

Advaxis (ADXS) said Friday it adjourned its special stockholder meeting to Dec. 7 to receive the approvals required to complete its planned merger with...

-- Earnings Flash (ADXS) ADVAXIS Reports Q3 Revenue $250M
9:22AM ET 9/10/2021 MT Newswires

...

Top Premarket Gainers
8:06AM ET 9/03/2021 MT Newswires

Cellect Biotech (APOP) shares soared 70% after the company disclosed the first bone marrow transplantation of ApoGraft in the US. Advaxis (ADXS) shares...

View all Commentary and Analysis

Advaxis: New Early Stage Pipeline Offers Significant, But Risky Upside
10:15PM ET 5/15/2021 Seeking Alpha

Company Profile

Business DescriptionAdvaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. View company web site for more details
Address9 Deer Park Drive
Princeton, New Jersey 08852
Phone+1.609.452.9813
Number of Employees58
Recent SEC Filing12/06/2021DEFA14A
President, Chief Executive Officer, CFO & DirectorKen Berlin
Chief Medical Officer & Executive Vice PresidentAndres A. GutiƩrrez
Vice President-Technical OperationsMichael Grace
Chief Accounting Officer & Vice President-FinanceIgor Gitelman

Company Highlights

Price Open$0.31
Previous Close$0.34
52 Week Range$0.29 - 1.57
Market Capitalization$50.2 M
Shares Outstanding145.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement01/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.20
Beta vs. S&P 500N/A
Revenue$6.1 M
Net Profit Margin-582.65%
Return on Equity-47.32%

Analyst Ratings as of 04/15/2021

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset